BioCentury
ARTICLE | Company News

MediGene cancer, autoimmune, infectious news

January 14, 2008 8:00 AM UTC

MediGene said it is looking at alternative financing options for its MediGene Ltd. subsidiary's monoclonal T cell receptor (mTCR) research program, including potentially spinning the program out. The program has multiple candidates in research and preclinical development to treat cancer, autoimmune diseases, allergy and infectious diseases. MediGene acquired the technology in its 2006 acquisition of Avidex Ltd. (see BioCentury, Sept. 4, 2006). The company expects the move will lead to a "significant reduction" in research expenses by 2009. ...